- Home
- FEMY
FEMY
Femasys Inc.
as 06-26-2025 4:00pm EST
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | SUWANEE |
| Market Cap: | 28.3M | IPO Year: | 2021 |
| Target Price: | $8.67 | AVG Volume (30 days): | 557.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.69 - $1.80 | Next Earning Date: | 08-07-2025 |
| Revenue: | $1,699,232 | Revenue Growth: | 61.97% |
| Revenue Growth (this year): | 231.84% | Revenue Growth (next year): | 245.28% |
Latest Femasys Inc. News
FEMY Breaking Stock News: Dive into FEMY Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Femasys Says FemBloc Non-Surgical Permanent Birth Control Gets European Approval; Shares Rise
GlobeNewswire
2 days ago
Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control
GlobeNewswire
10 days ago
Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth
GlobeNewswire
16 days ago
Femasys Announces Partnership with Carolinas Fertility Institute, One of America’s Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations
GlobeNewswire
a month ago
Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million
MT Newswires
a month ago
Femasys Plans Public Offering, Concurrent Private Placement
GlobeNewswire
a month ago
Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
Zacks
2 months ago
Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates
Compare FEMY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FEMY Femasys Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.